FDA Chief Counsel Warning Letter Review To Continue After Troy’s Departure
This article was originally published in The Tan Sheet
Executive Summary
The FDA Office of Chief Counsel's review of warning and untitled letters has resulted in the rejection of approximately 5% of letters, outgoing Chief Counsel Daniel Troy said